United Kingdom (UK)
Recombinant monoclonal antibody to VEGFR2. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from The phage display antibody V2.
UniProt Accession Number of Target Protein: P35968
Alternative Name(s) of Target: Vascular endothelial growth factor receptor 2; KDR; VEGFR-2; Fetal liver kinase 1; FLK-1; Kinase insert domain receptor; Protein-tyrosine kinase receptor flk-1; CD309
Immunogen: The original human version of this antibody was created by screening a human phage display library with VEGFR2-Fc.
Specificity: This antibody is specific for the VEGFR2 protein. It shows no binding to individual domains 2-3, 1-3 and 1-4. VEGFR2 is a tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. It plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells.
Application Notes: The human version of this antibody was tested by ELISA with different domains of VEGFR2 (WO2017004254). Furthermore, binding of the human version of this antibody to human umbilical vein endothelial cells was demostrated using flow cytometry (WO2017004254). After that, HUVEC tube formation assays were preformed using the human version of this antibody. This antibody did not show significant inhibition of tube formation (WO2017004254). Further, a matrigel plug assay was preformed using the human version of this antibody to asses its ability to inhibit angiogenesis in vivo (WO2017004254).
Antibody first published in:
Wei-dong et al. Anti-vascular endothelial growth factor receptor 2 (vegfr2) antibodies WO2017004254 PMID:
Note on publication:
Describes the generation and characterization of this antibdy.